Katia Mazzocco

List of Publications by Year in descending order

50 papers	1,609 citations	304743 22 h-index	302126 39 g-index
53 all docs	53 docs citations	53 times ranked	1774 citing authors

#	Article	IF	Citations
1	Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants. , 2021, 9, e002293.		25
2	Molecular Genetics in Neuroblastoma Prognosis. Children, 2021, 8, 456.	1.5	10
3	Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Journal of Clinical Oncology, 2021, 39, 3377-3390.	1.6	30
4	19p loss is significantly enriched in older age neuroblastoma patients and correlates with poor prognosis. Npj Genomic Medicine, 2020, 5, 18.	3.8	31
5	A Review of Infants With Localized Neuroblastoma That Evolve to Stage 4s Disease. Journal of Pediatric Hematology/Oncology, 2020, 42, e483-e487.	0.6	5
6	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. Journal of Clinical Oncology, 2020, 38, 3685-3697.	1.6	9
7	Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study. Cancers, 2019, 11, 1476.	3.7	43
8	Stage 4â€‰s neuroblastoma: features, management and outcome of 268 cases from the Italian Neuroblastoma Registry. Italian Journal of Pediatrics, 2019, 45, 8.	2.6	17
9	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. Journal of the National Cancer Institute, 2018, 110, 1084-1093.	6.3	73
10	Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study. British Journal of Cancer, 2018, 118, 1502-1512.	6.4	28
11	Somatic mutations in specific and connected subpathways are associated with short neuroblastoma patientsâ€™ survival and indicate proteins targetable at onset of disease. International Journal of Cancer, 2018, 143, 2525-2536.	5.1	27
12	Constitutional 3p26.3 terminal microdeletion in an adolescent with neuroblastoma. Cancer Biology and Therapy, 2017, 18, 285-289.	3.4	10
13	Genetic abnormalities in adolescents and young adults with neuroblastoma: A report from the Italian Neuroblastoma Group. Pediatric Blood and Cancer, 2015, 62, 1725-1732.	1.5	25
14	Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. British Journal of Cancer, 2015, 112, 290-295.	6.4	39
15	Neuroblastoma in the Adult. Journal of Pediatric Hematology/Oncology, 2014, 36, e499-e505.	0.6	10
16	Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy. European Journal of Medical Genetics, 2013, 56, 626-634.	1.3	12
17	Bone Marrow-Infiltrating Human Neuroblastoma Cells Express High Levels of Calprotectin and HLA-G Proteins. PLoS ONE, 2012, 7, e29922.	2.5	40
18	Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.4	82

#	Article	IF	Citations
19	Simultaneous tumors: Acute myeloid leukemia infiltrating mediastinal ganglioneuroblastoma. Pediatric Blood and Cancer, 2011, 56, 298-300.	1.5	1
20	A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma. Clinical Cancer Research, 2011, 17, 792-804.	7.0	39
21	Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, highâ€risk, neuroblastic tumor patients. International Journal of Cancer, 2010, 126, 656-668.	5.1	35
22	MDM2 SNP309 genotype is associated with ferritin and LDH serum levels in children with stage 4 neuroblastoma. Pediatric Blood and Cancer, 2010, 55, 267-272.	1.5	5
23	MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma. Pediatric Blood and Cancer, 2009, 53, 576-583.	1.5	17
24	The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. International Journal of Biological Markers, 2009, 24, 119-129.	1.8	6
25	Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma. European Journal of Cancer, 2008, 44, 2634-2639.	2.8	17
26	Concomitant DDX1 and MYCN gain in neuroblastoma. Cancer Letters, 2007, 256, 56-63.	7.2	8
27	Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization. Cancer Genetics and Cytogenetics, 2007, 177, 20-29.	1.0	39
28	Neuroblastoma in adolescents. Cancer, 2006, 106, 1409-1417.	4.1	65
29	Oligonucleotide Array Comparative Genomic Hybridization Profiling of Neuroblastoma Tumours. Cancer Genomics and Proteomics, 2006, 3, 245-252.	2.0	1
30	Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells. Journal of Pathology, 2005, 207, 346-357.	4.5	36
31	Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization. Molecular Diagnosis and Therapy, 2004, 8, 93-100.	1.1	17
32	Detection of MYCN Amplification and Chromosome 1p36 Loss in Neuroblastoma by cDNA Microarray Comparative Genomic Hybridization. Molecular Diagnosis and Therapy, 2004, 8, 93-100.	1.1	4
33	Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 442, 555-562.	2.8	68
34	Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma. American Journal of Medical Genetics Part A, 2003, 118A, 309-313.	2.4	35
35	Biological and clinical role of p73 in neuroblastoma. Cancer Letters, 2003, 197, 111-117.	7.2	19
36	Quality Assessment of Genetic Markers Used for Therapy Stratification. Journal of Clinical Oncology, 2003, 21, 2077-2084.	1.6	113

#	Article	IF	Citations
37	Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Annals of Oncology, 2002, 13, 956-964.	1.2	31
38	Two regions of deletion in 9p22âˆ¼p24 in neuroblastoma are frequently observed in favorable tumors. Cancer Genetics and Cytogenetics, 2002, 135, 42-47.	1.0	20
39	Expression of Î”Np73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death and Differentiation, 2002, 9, 246-251.	11.2	183
40	Comprehensive Genetic and Histopathologic Study Reveals Three Types of Neuroblastoma Tumors. Journal of Clinical Oncology, 2001, 19, 3080-3090.	1.6	103
41	Neuroblastoma in Two Siblings Supports the Role of 1p36 Deletion in Tumor Development. Cancer Genetics and Cytogenetics, 1999, 109, 126-130.	1.0	13
42	Stage-independent expression and genetic analysis oftp73 in neuroblastoma. International Journal of Cancer, 1999, 84, 365-369.	5.1	14
43	Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavourable outcome. Cancer Letters, 1998, 130, 83-92.	7.2	19
44	Restriction fragment length polymorphism analysis reveals different allele frequency and a linkage disequilibrium at locus D1S94 in neuroblastoma patients. European Journal of Cancer, 1997, 33, 1949-1952.	2.8	3
45	Loss of heterozygosity for chromosome 1p in familial neuroblastoma. European Journal of Cancer, 1997, 33, 1953-1956.	2.8	9
46	MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.. Journal of Clinical Oncology, 1997, 15, 85-93.	1.6	111
47	Evidence of apoptosis in neuroblastoma at onset and relapse. An analysis of a large series of tumors. Journal of Neuro-Oncology, 1997, 31, 217-223.	2.9	16
48	Peculiar allelotype associated with susceptibility to neuroblastoma. , 1996, 17, 60-63.		4
49	Gene expression and protein localisation of calcyclin, a calcium-binding protein of the S-100 family in fresh neuroblastomas. European Journal of Cancer, 1995, 31, 499-504.	2.8	24
50	Identification of an AP-1-like sequence in the promoter region of calcyclin, a S-100-like gene. Enhancement of binding during retinoic acid-induced neuroblastoma cell differentiation. Neuroscience Letters, 1994, 181, 35-38.	2.1	15